Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17β-estradiol in an in vivo model of myocardial ischemia and reperfusion

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 3, 2007, Pages

  Booth, Erin A ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Complement; Lipid peroxidation; Medroxyprogesterone acetate; Membrane attack complex

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IN VIVO STUDY; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ESTRADIOL; HEART; HEART RATE; MALE; MALONDIALDEHYDE; MEDROXYPROGESTERONE 17-ACETATE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RABBITS; REPERFUSION INJURY; TROPONIN I;

EID: 34548422393     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00993.2006     Document Type: Article

References (43)

1. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC. Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras. J Biol Chem 275: 1739-1748, 2000.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004.
3. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein- associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther 303: 1007-1013, 2002.
4. Booth EA, Marchesi M, Kilbourne EJ, Lucchesi BR. 17β-Estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther 307: 395-401, 2003.
5. Booth EA, Obeid NR, Lucchesi BR. Activation of estrogen receptor-α protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 289: H2039-H2047, 2005.
6. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840-845, 2007.
7. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100: 717-722, 1999.
8. De Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47: 239-243, 1982.
9. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. Cyclooxygenase-2-derived prostacyclin confers atheroprotection on female mice. Obstet Gynecol Surv 60: 309-310, 2005.
10. Furie B, Furie BC. Leukocyte crosstalk at the vascular wall. Thromb Haemost 78: 306-309, 1997.
11. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313, 1995.
12. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57, 2002.
13. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190: 1733-1740, 1999.
14. Guetta V, Cannon RO 3rd. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 93: 1928-1937, 1996.
15. Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, Van Gulik TM. Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol 143: 15-23, 2006.
16. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133: 885-900, 1971.
17. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, Reuben DB. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185: 347-352, 2005.
18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998.
19. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better? JAMA 291: 1769-1771, 2004.
20. Krause DN, Duckles SP, Pelligrino DA. Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol 101: 1252-1261, 2006.
21. Lucchesi BR. Complement, neutrophils and free radicals: mediators of reperfusion injury. Arzneimittelforschung 44: 420-432, 1994.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979.
23. Pascual M, Catana E, Spertini F, Macon K, Volanakis JE, Schifferli JA. A monoclonal antibody which blocks the function of factor D of human complement. J Immunol Methods 127: 263-269, 1990.
24. Pasinetti GM, Tocco G, Sakhi S, Musleh WD, DeSimoni MG, Mascarucci P, Schreiber S, Baudry M, Finch CE. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis 3: 197-204, 1996.
25. Pelzer T, Neumann M, de Jager T, Jazbutyte V, Neyses L. Estrogen effects in the myocardium: inhibition of NF-κB DNA binding by estrogen receptor-α and -β. Biochem Biophys Res Commun 286: 1153-1157, 2001.
26. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288: 980-987, 2002.
27. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18: 1164-1171, 1998.
28. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 22: 1207-1213, 1992.
29. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol 155: 2203-2210, 1995.
30. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731-733, 1998.
31. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100: 713-716, 1999.
32. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
33. Sbarouni E, Iliodromitis EK, Bofilis E, Kyriakides ZS, Kremastinos DT. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol 467: 163-168, 2003.
34. Sunday L, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab 291: E261-E267, 2006.
35. Tanhehco EJ, Lee H, Lucchesi BR. Sublytic complement attack reduces infarct size in rabbit isolated hearts: evidence for C5a-mediated cardioprotection. Immunopharmacology 49: 391-399, 2000.
36. Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Kilgore KS, Homeister JW, Lucchesi BR. Preconditioning reduces tissue complement gene expression in the rabbit isolated heart. Am J Physiol Heart Circ Physiol 277: H2373-H2380, 1999.
37. Tsai CH, Su SF, Chou TF, Lee TM. Differential effects of sarcolemmal and mitochondrial KATP channels activated by 17β-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts. J Pharmacol Exp Ther 301: 234-240, 2002.
38. Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, Maggi A. Estrogen receptor-α mediates the brain anti-inflammatory activity of estradiol. Proc Natl Acad Sci USA 100: 9614-9619, 2003.
39. Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 389: 235-250, 1982.
40. Writing G. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI trial. JAMA 273: 199-208, 1995.
41. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109: 234-241, 2004.
42. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104: 974-975, 2001.
43. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA 84: 1404-1407, 1987.